SRD5A2 Polymorphisms and Risk of Prostate Cancer in Men with Benign Prostate Hyperplasia

Prostate cancer (PRCa) is one of the most common causes of cancer death in men and determinants of PRCa risk remain largely unidentified. This study design to assess the predictive value of three polymorphisms in SRD5A2 to determine the risk of developing PRCa in patients with benign prostatic hyperplasia (BPH). The study evaluated 28 patients who presented with PRCa at least 6 years after the diagnosis of BPH and 56 matched patients with BPH who did not progress to PRCa over a comparable period. Polymorphisms V89L and A49T were detected by RFLP analysis and The (TA)n repeats was determined using an ABI PRISM 310 Genetic analyser. BPH patients with (TA)0 allele of the (TA)n marker had statistically no significant risk of developing PRCa (OR: 3.24, 95% CI= 0.37-28.33) compared with BPH patients with (TA)9 allele. For the V89L marker, The OR for risk of developing PRCa was 1.29 (95% CI= 0.69-2.40) in BPH patients having a V allele. The frequency of the A49T TT genotype was higher in cases (7%) compared to control subjects (2%), although this was not statistically significant (OR=1.3, 95% CI=0.55-3.10). This is the first study effort to examine the role of SRD5A2 polymorphisms (V89L, A49T and (TA)n) in the development of PRCa in patients with BPH. Although this study found no statistically significant association of these three polymorphic markers with PRCa risk in BPH patients, a modest effect can not be ruled out.